Comment Letters

• WCCC Comment Letter to FDA Real World Evidence Guidance

• Comment Letter re: LCD Skin Substitute Grafts/ Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers | August 2023

Publications

• PROTOCOL: A novel randomized trial protocol for evaluating wound healing interventions.

• New Federal Incentives for Diversity in Clinical Trials

• A Vision of Medicare Coverage for New and Emerging Technologies – A Consistent Process to Foster Innovation and Promote Value

• Identification and content validation of wound therapy clinical endpoints relevant to clinical practice and patient values for FDA approval. Part 1. Survey of the wound care community

• Evidence supporting wound care end points relevant to clinical practice and patients’ lives. Part 2. Literature survey

• Evidence supporting wound care end points relevant to clinical practice and patients’ lives. Part 3: The Patient Survey

• When an Opportunity Knocked, the Wound Care Community Responded

• Innovation in wound care products: a FDA regulatory perspective

Presentations

Member Meeting – 10/24/2023

Member Meeting – 07/25/2023

Member Meeting – 04/18/2023

Member Meeting – 01/10/2023

Member Meeting – 09/27/2022

Member Meeting – 06/21/2022

Member Meeting – 04/26/2022

Member Meeting – 03/01/2022

Member Meeting – 01/04/2022

Member Meeting – 06/16/2021

Member Meeting – 05/05/2021

Members Representing Many

• Clinicians (interdisciplinary, university, private & hospital based)
• Academia (researchers and clinicians)
• Government (FDA, VA, DOD, CMS)
• Associations and Societies (national and international)
• Industry (device, biologics, pharmaceuticals, diagnostics)
• Patients and Caregivers
• Health Care Insurance Companies